Evidence map›Paper›PMID 41060491›Full record

ArticleDermatology and therapy2025

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07169682 (Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07169682 completednot on this map

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis: an Observational Study

TypeobservationalSponsorNational and Kapodistrian University of AthensRan2021 to 2024Enrolled66ConditionsPsoriasis, Cardiovascular Disease, AtherosclerosisArmsinterleukin 17 inhibitor, interleukin-23 inhibitor, conventional systemic agent or apremilast
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aikaterini TsiogkaFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece. a.tsiogka@yahoo.com.ORCID http://orcid.org/0000-0002-6853-9788
Stergios SoulaidopoulosFirst Cardiology Department, Hippokration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Stamatios GregoriouFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Natalia RompotiFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Pantelis PanagakisFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Marina PapoutsakiFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Panagiotis KostakisFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
George KontochristopoulosFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Konstantinos TsioufisFirst Cardiology Department, Hippokration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Charalambos VlachopoulosFirst Cardiology Department, Hippokration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527, Athens, Greece.
Alexander StratigosFirst Department of Dermatology-Venereology, Faculty of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, 5 I. Dragoumi St., 16121, Athens, Greece.
Dimitrios RigopoulosDermatology Department, Hygeia Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.

methodsThis observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).

resultsIn total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.

conclusionsBoth IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.

Indexed as

Arterial stiffnessAtherosclerosisAugmentation indexBiologicsPsoriasisPulse wave velocity

Identifiers

PMID41060491
PMCPMC12619868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.